Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.

Hdl Handle:
http://hdl.handle.net/10144/142609
Title:
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.
Authors:
Bygrave, Helen; Ford, Nathan; van Cutsem, Gilles; Hilderbrand, Katherine; Jouquet, Guillaume; Goemaere, Eric; Vlahakis, Nathalie; Triviño, Laura; Makakole, Lipontso; Kranzer, Katharina
Journal:
Journal of Acquired Immune Deficiency Syndromes (1999)
Abstract:
The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho.
Affiliation:
Médecins Sans Frontières, Morija, Lesotho. helen.bygrave@joburg.msf.org
Issue Date:
Mar-2011
URI:
http://hdl.handle.net/10144/142609
DOI:
10.1097/QAI.0b013e3182097505
PubMed ID:
21164354
Language:
en
ISSN:
1944-7884
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorBygrave, Helenen
dc.contributor.authorFord, Nathanen
dc.contributor.authorvan Cutsem, Gillesen
dc.contributor.authorHilderbrand, Katherineen
dc.contributor.authorJouquet, Guillaumeen
dc.contributor.authorGoemaere, Ericen
dc.contributor.authorVlahakis, Nathalieen
dc.contributor.authorTriviño, Lauraen
dc.contributor.authorMakakole, Lipontsoen
dc.contributor.authorKranzer, Katharinaen
dc.date.accessioned2011-09-19T14:06:10Z-
dc.date.available2011-09-19T14:06:10Z-
dc.date.issued2011-03-
dc.identifier.citationImplementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. 2011, 56 (3):e75-8 J. Acquir. Immune Defic. Syndr.en
dc.identifier.issn1944-7884-
dc.identifier.pmid21164354-
dc.identifier.doi10.1097/QAI.0b013e3182097505-
dc.identifier.urihttp://hdl.handle.net/10144/142609-
dc.description.abstractThe latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho.en
dc.language.isoenen
dc.rightsArchived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)en
dc.subject.meshAdenineen
dc.subject.meshAdulten
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntiretroviral Therapy, Highly Activeen
dc.subject.meshCohort Studiesen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHumansen
dc.subject.meshLesothoen
dc.subject.meshMaleen
dc.subject.meshPhosphonic Acidsen
dc.subject.meshPregnancyen
dc.subject.meshPregnancy Complications, Infectiousen
dc.subject.meshRural Populationen
dc.subject.meshTreatment Outcomeen
dc.titleImplementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.en
dc.contributor.departmentMédecins Sans Frontières, Morija, Lesotho. helen.bygrave@joburg.msf.orgen
dc.identifier.journalJournal of Acquired Immune Deficiency Syndromes (1999)en

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.